All Phenotypes Cdc25b<tm1Pjd> MGI Mouse

About Help FAQ

Phenotypes associated with this allele

Allele Symbol
Allele Name
Allele ID

Cdc25b^tm1Pjd
targeted mutation 1, Peter J Donovan
MGI:2682953

Summary

5 genotypes

Jump to	Allelic Composition	Genetic Background	Genotype ID
hm1	Cdc25b^tm1Pjd/Cdc25b^tm1Pjd	Not Specified	MGI:2682957
cn2	Cdc25a^tm1Hpw/Cdc25a^tm1.1Hpw Cdc25b^tm1Pjd/Cdc25b^tm1Pjd Cdc25c^tm1Hpw/Cdc25c^tm1Hpw Gt(ROSA)26Sor^{tm1(cre/ERT)Brn}/Gt(ROSA)26Sor⁺	involves: 129P2/OlaHsd * 129X1/SvJ * C57BL/6	MGI:3845392
cn3	Cdc25a^tm1Hpw/Cdc25a^tm1.1Hpw Cdc25b^tm1Pjd/Cdc25b^tm1Pjd Tg(Vil1-cre/ERT2)23Syr/0	involves: 129X1/SvJ * C57BL/6 * DBA/2	MGI:4941917
cn4	Cdc25a^tm1Hpw/Cdc25a^tm1.1Hpw Cdc25b^tm1Pjd/Cdc25b^tm1Pjd Cdc25c^tm1Hpw/Cdc25c^tm1Hpw Tg(Vil1-cre/ERT2)23Syr/0	involves: 129X1/SvJ * C57BL/6 * DBA/2	MGI:4941918
cn5	Cdc25b^tm1Hpw/Cdc25b^tm1Pjd Tg(Vil1-cre/ERT2)23Syr/0	involves: 129X1/SvJ * C57BL/6 * DBA/2	MGI:4943329

Allelic Composition	Cdc25b^tm1Pjd/Cdc25b^tm1Pjd
Genetic Background	Not Specified

Find Mice

Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Cdc25b^tm1Pjd mutation (0 available); any Cdc25b mutation (30 available)

♀	phenotype observed in females
♂	phenotype observed in males
N	normal phenotype

reproductive system

abnormal oocyte morphology ( J:87011 )

• MPF is not activated in oocytes and they do not undergo germinal vesicle breakdown

• folliculogenesis and ovulation were unimpaired

abnormal female meiosis ( J:87011 )

• while spermatogenesis was unaffected, the female meiotic cycle was arrested at prophase I due to an inability to activate maturation-promoting factor (MPF)

abnormal reproductive system physiology ( J:87011 )

female infertility ( J:87011 )

cellular

abnormal oocyte morphology ( J:87011 )

• MPF is not activated in oocytes and they do not undergo germinal vesicle breakdown

• folliculogenesis and ovulation were unimpaired

Allelic Composition	Cdc25a^tm1Hpw/Cdc25a^tm1.1Hpw Cdc25b^tm1Pjd/Cdc25b^tm1Pjd Cdc25c^tm1Hpw/Cdc25c^tm1Hpw Gt(ROSA)26Sor^{tm1(cre/ERT)Brn}/Gt(ROSA)26Sor⁺
Genetic Background	involves: 129P2/OlaHsd * 129X1/SvJ * C57BL/6

Find Mice

Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Cdc25a^tm1.1Hpw mutation (1 available); any Cdc25a mutation (34 available)
Cdc25a^tm1Hpw mutation (1 available); any Cdc25a mutation (34 available)
Cdc25b^tm1Pjd mutation (0 available); any Cdc25b mutation (30 available)
Cdc25c^tm1Hpw mutation (1 available); any Cdc25c mutation (23 available)
Gt(ROSA)26Sor^{tm1(cre/ERT)Brn} mutation (1 available); any Gt(ROSA)26Sor mutation (942 available)

♀	phenotype observed in females
♂	phenotype observed in males
N	normal phenotype

Shortened villi in the small intestine of Cdc25a^tm1Hpw/Cdc25a^tm1.1Hpw Cdc25b^tm1Pjd/Cdc25b^tm1Pjd Cdc25c^tm1Hpw/Cdc25c^tm1Hpw Gt(ROSA)26Sor^{tm1(cre/ERT)Brn}/Gt(ROSA)26Sor⁺ (TKO) mice

mortality/aging

premature death ( J:145768 )

• adult mice die within 1 week of initial 4-hydroxytamoxifen (OHT) injection

growth/size/body

weight loss ( J:145768 )

• adult mice exhibit significant weight loss (20%) within 1 week of initial tamoxifen injection

digestive/alimentary system

abnormal small intestine crypts of Lieberkuhn morphology ( J:145768 )

• profound cell atrophy in the crypts is observed in OHT-treated mice; crypts are >40% smaller in mutants than Cdc25a-single knockout controls, with the crypt width being decreased more significantly than the depth

• a 70% loss of epithelial cells per crypt is detected, but no difference in mature Paneth cells is observed

• decreased proliferation of epithelial cells is observed, with no significant increase in apoptotic cell numbers; this results in premature differentiation of cell progenitors below Paneth cell compartments in crypts

• crypts have increased numbers of cells exhibiting early differentiation with no crypt base columnar (CBC) cells

abnormal small intestinal villus morphology ( J:145768 )

• villi are lined with shorter, less-dense enterocytes in proximal regions; complete loss of distal villi is observed in some areas

decreased small intestinal villus height ( J:145768 )

• significant loss of villus height in proximal and distal regions is observed in mutants after OHT treatment

decreased small intestine length ( J:145768 )

• 6 days following the final of 3 consecutive injections of tamoxifen, length of small intestine is shortened by 40% compared to controls

endocrine/exocrine glands

abnormal small intestine crypts of Lieberkuhn morphology ( J:145768 )

• a 70% loss of epithelial cells per crypt is detected, but no difference in mature Paneth cells is observed

• crypts have increased numbers of cells exhibiting early differentiation with no crypt base columnar (CBC) cells

Allelic Composition	Cdc25a^tm1Hpw/Cdc25a^tm1.1Hpw Cdc25b^tm1Pjd/Cdc25b^tm1Pjd Tg(Vil1-cre/ERT2)23Syr/0
Genetic Background	involves: 129X1/SvJ * C57BL/6 * DBA/2

Find Mice

♀	phenotype observed in females
♂	phenotype observed in males
N	normal phenotype

mortality/aging

postnatal lethality, incomplete penetrance ( J:169457 )

• 2 of 5 tamoxifen-treated mice die by day 8

digestive/alimentary system

increased enterocyte apoptosis ( J:169457 )

• in tamoxifen-treated mice

abnormal enterocyte differentiation ( J:169457 )

• tamoxifen-treated mice exhibit premature differentiation of small intestine crypt cells compared with control mice

abnormal small intestinal crypt cell proliferation ( J:169457 )

• tamoxifen-treated mice exhibit decreased S-phase cells in crypts compared with control mice

abnormal large intestine morphology ( J:169457 )

• reduced length in tamoxifen-treated mice

abnormal small intestine morphology ( J:169457 )

• reduced length in tamoxifen-treated mice

abnormal small intestine crypts of Lieberkuhn morphology ( J:169457 )

• tamoxifen treated mice exhibit a reduction in epithelium cells in the small intestine crypts compared with control mice

• however, the number of Paneth cells is normal

decreased small intestinal villus size ( J:169457 )

• in tamoxifen-treated mice

growth/size/body

decreased body weight ( J:169457 )

• in tamoxifen-treated mice

endocrine/exocrine glands

abnormal small intestine crypts of Lieberkuhn morphology ( J:169457 )

• tamoxifen treated mice exhibit a reduction in epithelium cells in the small intestine crypts compared with control mice

• however, the number of Paneth cells is normal

cellular

increased enterocyte apoptosis ( J:169457 )

• in tamoxifen-treated mice

abnormal enterocyte differentiation ( J:169457 )

• tamoxifen-treated mice exhibit premature differentiation of small intestine crypt cells compared with control mice

abnormal small intestinal crypt cell proliferation ( J:169457 )

• tamoxifen-treated mice exhibit decreased S-phase cells in crypts compared with control mice

Allelic Composition	Cdc25a^tm1Hpw/Cdc25a^tm1.1Hpw Cdc25b^tm1Pjd/Cdc25b^tm1Pjd Cdc25c^tm1Hpw/Cdc25c^tm1Hpw Tg(Vil1-cre/ERT2)23Syr/0
Genetic Background	involves: 129X1/SvJ * C57BL/6 * DBA/2

Find Mice

♀	phenotype observed in females
♂	phenotype observed in males
N	normal phenotype

mortality/aging

postnatal lethality, incomplete penetrance ( J:169457 )

• 5 of 11 tamoxifen-treated mice die by day 8

digestive/alimentary system

increased enterocyte apoptosis ( J:169457 )

• in tamoxifen-treated mice

abnormal enterocyte differentiation ( J:169457 )

• tamoxifen-treated mice exhibit premature differentiation of small intestine crypt cells compared with control mice

abnormal small intestinal crypt cell proliferation ( J:169457 )

• tamoxifen-treated mice exhibit decreased S-phase cells in crypts compared with control mice

abnormal large intestine morphology ( J:169457 )

• reduced length in tamoxifen-treated mice

abnormal small intestine morphology ( J:169457 )

• reduced length in tamoxifen-treated mice

abnormal small intestine crypts of Lieberkuhn morphology ( J:169457 )

• tamoxifen treated mice exhibit a reduction in epithelium cells in the small intestine crypts compared with control mice

• however, the number of Paneth cells is normal

decreased small intestinal villus size ( J:169457 )

• in tamoxifen-treated mice

growth/size/body

decreased body weight ( J:169457 )

• in tamoxifen-treated mice

endocrine/exocrine glands

abnormal small intestine crypts of Lieberkuhn morphology ( J:169457 )

• tamoxifen treated mice exhibit a reduction in epithelium cells in the small intestine crypts compared with control mice

• however, the number of Paneth cells is normal

cellular

increased enterocyte apoptosis ( J:169457 )

• in tamoxifen-treated mice

abnormal enterocyte differentiation ( J:169457 )

• tamoxifen-treated mice exhibit premature differentiation of small intestine crypt cells compared with control mice

abnormal small intestinal crypt cell proliferation ( J:169457 )

• tamoxifen-treated mice exhibit decreased S-phase cells in crypts compared with control mice

Allelic Composition	Cdc25b^tm1Hpw/Cdc25b^tm1Pjd Tg(Vil1-cre/ERT2)23Syr/0
Genetic Background	involves: 129X1/SvJ * C57BL/6 * DBA/2

Find Mice

Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Cdc25b^tm1Hpw mutation (1 available); any Cdc25b mutation (30 available)
Cdc25b^tm1Pjd mutation (0 available); any Cdc25b mutation (30 available)
Tg(Vil1-cre/ERT2)23Syr mutation (1 available)

♀	phenotype observed in females
♂	phenotype observed in males
N	normal phenotype

digestive/alimentary system

digestive/alimentary phenotype ( J:169457 )

N	• tamoxifen-treated mice exhibit normal intestine morphology

growth/size/body

growth/size/body region phenotype ( J:169457 )

N	• tamoxifen-treated mice exhibit normal body weight

Contributing Projects: Mouse Genome Database (MGD), Gene Expression Database (GXD), Mouse Models of Human Cancer database (MMHCdb) (formerly Mouse Tumor Biology (MTB)), Gene Ontology (GO)
Citing These Resources Funding Information Warranty Disclaimer, Privacy Notice, Licensing, & Copyright Send questions and comments to User Support.	last database update 04/16/2024 MGI 6.23